OncLive TV

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the future of surgery in head and neck cancer.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using CAR T-cell therapy in solid tumors.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non-small cell lung cancer.

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy combinations in the treatment of patients with renal cell carcinoma (RCC).

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

Thomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.